Delving into the Latest Updates on Chuangzhixing (Guangzhou) Biotechnology Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Mesenchymal stem cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Mesenchymal stem cell therapy	1

（1）主要目的：评价E10I在2型糖尿病患者中静脉输注的安全性与耐受性，确定临床用药安全范围。（2）次要目的：评价E10I在2型糖尿病患者中静脉输注的初步有效性（3）探索目的：在部分女性患者中，探索E10I静脉输注的药代动力学（PK）特征

[Translation]

(1) Primary objective: To evaluate the safety and tolerability of intravenous infusion of E10I in patients with type 2 diabetes and to determine the safety range of clinical medication. (2) Secondary objective: To evaluate the preliminary efficacy of intravenous infusion of E10I in patients with type 2 diabetes. (3) Exploratory objective: To explore the pharmacokinetic (PK) characteristics of intravenous infusion of E10I in selected female patients.

Start Date-

Sponsor / Collaborator

Chuangzhixing (Guangzhou) Biotechnology Co., Ltd.

[+1]

100 Clinical Results associated with Chuangzhixing (Guangzhou) Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Chuangzhixing (Guangzhou) Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Chuangzhixing (Guangzhou) Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Chuangzhixing (Guangzhou) Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data